Transgene - First Patient Dosed in Phase I Trial Evaluating

TG6050 is an oncolytic virus derived from Transgene's Invir.IO® platform encoding interleukin-12 (IL-12) and an anti-CTLA4 antibody, with the potential to trigger a powerful antitumor immune response.

Related Keywords

United States , Copenhagen , Køavn , Denmark , American , Maud Brandely , Lucie Larguier , Sylvie Berrebi , Transgene Euronext , American Association For Cancer Research , Twitter , Corporate Communications , Phasei Delivir , Euronext Paris , Chief Medical Officer , American Association , Cancer Research , Annual Meeting , Artificial Intelligence , Risk Factors , Universal Registration Document , Gefallene Big Techs , Transgene , First , Patient , Hosed , Hase , Trial , Valuating , G6050 , Novel , Armed , Ncolytic , Virus , Administered , Intravenously , Mall , Fell , Young , Dancer ,